75.30
+1.21%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pharmanutra SpA
Its shares trade on Borsa Italiana under the ticker PHN.MI. It has been listed since 18 July 2017. In the fiscal year to 31 December 2025, it reported revenue of €131.7m and net income of €20.0m. At that date it held total assets of €125.2m and shareholders' equity of €71.4m.
Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Consumer Staples
- Industry
- Personal Products
- Listed since
- 18 Jul 2017
- Employees
- 54
- Website
- pharmanutra.it/it ↗
Leadership
Pay as last reported
- Mr. Andrea LacorteExecutive Chairman of the Board, since 2003€2.4m
- Mr. Roberto LacorteExecutive Vice Chairman of the Board, since 2003€2.1m
- Mr. Carlo VolpiChief Marketing Officer, Executive Director, since 2008€2.0m
- Mr. Germano TarantinoExecutive Director, since 2011€615,557
- Mr. Alessandro CalzolariLead Independent Non-Executive Director€44,000
- Ms. Marida ZaffaroniNon-Executive Independent Director€44,000
- Ms. Giovanna ZanottiNon-Executive Independent Director€44,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 54
- Environment
- 40
- Social
- 97
- Governance
- 25
- Direct emissions (scope 1)
- 229.189 t
- Energy emissions (scope 2)
- 186.46 t
- Women in the workforce
- 58%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pharmanutra SpA has several strengths that contribute to its success in the market. Firstly, the company has a strong brand reputation and recognition. This is due to their commitment to providing high-quality and innovative healthcare products. Moreover, Pharmanutra SpA has a diverse and wide range of products, catering to different segments of the market. This allows them to capture a larger customer base and increase their market share. Additionally, the company has a well-established distribution network, ensuring their products reach customers efficiently and effectively.
Weaknesses
- Pharmanutra SpA also faces certain weaknesses that need to be addressed in order to maintain their competitive edge. One significant weakness is their heavy reliance on external suppliers for raw materials. This exposes the company to potential supply chain disruptions and fluctuations in prices. Furthermore, Pharmanutra SpA's research and development capabilities are not as advanced as some of their competitors, limiting their ability to introduce groundbreaking products and technologies. Addressing these weaknesses is crucial for sustained growth and competitiveness.
Opportunities
- Pharmanutra SpA operates in a dynamic market with several opportunities for growth. One significant opportunity is the increasing demand for natural and organic healthcare products. By capitalizing on this trend, Pharmanutra SpA can expand their product portfolio to cater to health-conscious consumers. Additionally, the company can explore emerging markets and expand their geographical presence to tap into new customer segments. Leveraging advances in technology, such as e-commerce and telemedicine, represents another opportunity for Pharmanutra SpA to enhance customer reach and convenience.
Threats
- Despite its strengths and opportunities, Pharmanutra SpA also faces various threats that pose challenges to its business. One significant threat is intense competition from both established pharmaceutical companies and emerging startups. Pricing pressures resulting from healthcare reforms and government regulations also pose a threat to profitability. Additionally, rapid changes in consumer preferences and trends can create challenges for Pharmanutra SpA in terms of adapting their product offerings and marketing strategies. It is important for the company to effectively navigate these threats in order to maintain a strong position in the market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.